Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Sarcoma 4Melanoma 4Breast Neoplasms 3Urinary Bladder Neoplasms 2Osteosarcoma 2Gliosarcoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tazemetostat 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × poly ICLC × Sarcoma × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡